ReviewCurrent hypertension reports2020
Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.
Review in Current hypertension reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- A systematic review and meta-analysis of the hyperuricemia risk from certain metals.Clinical rheumatology · 2022Pooled it
- Exploring urinary allantoin and adenosine in pediatric autosomal dominant polycystic kidney disease: no clear association with disease severity.Pediatric nephrology (Berlin, Germany) · 2026Observational
- The study on cerebral variations and cognitive function in male patients with hyperuricemia using amide proton transfer imaging.Quantitative imaging in medicine and surgery · 2026Article
- Serum uric acid and its metabolism-a vital factor in the inflammatory transformation of cancer.Journal of advanced research · 2026Review
- Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026Review
- Article
- Dual Mechanisms of Naru Sanwei Pills in Gout: NLRP3 Inflammasome Inhibition and Uric Acid Regulation.Journal of inflammation research · 2026Article
- Uric Acid-Degrading Lacticaseibacillus paracasei CPU202306 Ameliorates Hyperuricemia by Regulating Uric Acid Metabolism and Intestinal Microecology in Mice.Probiotics and antimicrobial proteins · 2026Article
- Tiliroside Suppresses Uric Acid Production in Hepatocytes and Attenuates Purine-Induced Hyperuricemia in Male ICR Mice.Molecules (Basel, Switzerland) · 2025Article
- Impact of Urate-Lowering Agents on Renal Outcomes in Chronic Kidney Disease: A Systematic Review.Cureus · 2025Review
- Phytotherapeutic insights into hyperuricemia: a mechanistic and clinical perspective.Inflammopharmacology · 2025Review
- Risk of incident gout in rheumatoid arthritis from a nationwide cohort study in South Korea.Scientific reports · 2025Article
- The Promise of Dotinurad for Hyperuricemia in CKD.Kidney international reports · 2025Article
- The Many Faces of Protease-Activated Receptor 2 in Kidney Injury.Biomedicines · 2025Review
- Bibliometric and visual assessment of research trends in the management of hyperuricemia (HUA).Clinical rheumatology · 2025Article
- Probiotic potential ofFrontiers in microbiology · 2025Article
- The effects ofFrontiers in microbiology · 2025Article
- Analysis of risk factors for abnormal renal function in patients with gout in Southwest China: a cross-sectional study.Rheumatology advances in practice · 2025Article
- Exercise and hyperuricemia: an opinion article.Annals of medicine · 2024Article
- Comorbidities confound metabolomics studies of human disease.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn chronic kidney disease (CKD), plasma uric acid levels are increased because of the decrease in glomerular filtration rate. However, in addition to CKD, hyperuricemia is frequently associated with a number of other conditions such as hypertension, type 2 diabetes, obesity, and heart failure, overweight, and cardiovascular disease. RECENT
findingsIt is now becoming increasingly clear that, in many clinical conditions, elevated levels of uric acid have a much greater role beyond just causing gout. The present review will summarize current knowledge on the relation between hyperuricemia, CKD, and existing comorbidities, as well as the mechanisms of uric acid-related renal damage. In addition, the role and evidence for urate-lowering therapy in prevention and cardiovascular protection in CKD patients is discussed with a focus on allopurinol and febuxostat. To date, several clinical studies have provided evidence that urate-lowering therapy may help to prevent and delay the decline of renal function in patients with CKD. Use of a xanthine oxidase inhibitor should be considered in patients who are at high renal risk and/or with declining renal function in the presence of hyperuricemia with and without deposition, although additional studies are warranted to define treatment targets. Notwithstanding, the possibility to delay deterioration of renal function in patients with CKD merits consideration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.